No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - General
Biogen Inc. is a prominent biopharmaceutical company dedicated to the research, development, production, and commercialization of therapeutic solutions for neurological and neurodegenerative disorders. Its extensive product lineup features treatments for multiple sclerosis (MS), including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA. For spinal muscular atrophy, the company offers SPINRAZA, and FUMADERM addresses plaque psoriasis. Furthermore, Biogen provides ADUHELM for Alzheimer's disease. The company's portfolio also encompasses various biosimilar products, such as BENEPALI (an etanercept biosimilar referencing ENBREL), IMRALDI (an adalimumab biosimilar referencing HUMIRA), and FLIXABI (an infliximab biosimilar referencing REMICADE). Beyond these, Biogen markets several anti-CD20 therapies. These include RITUXAN, used in conditions like non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, specific forms of ANCA-associated vasculitis, and pemphigus vulgaris. RITUXAN HYCELA is also available for non-Hodgkin's lymphoma and CLL, while GAZYVA targets CLL and follicular lymphoma. OCREVUS is another key offering, treating both relapsing and primary progressive MS. A robust pipeline underscores Biogen's future focus, with drug candidates in development across multiple areas. These include compounds for MS and neuroimmunology (BIIB135, BIIB061, BIIB091, BIIB107); Alzheimer's disease and dementia (Aducanumab, Lecanemab, BIIB076, BIIB080); neuromuscular disorders (BIIB067, BIIB078, BIIB105, BIIB100, BIIB110); Parkinson's disease and movement disorders (BIIB124, BIIB094, BIIB118, BIIB101, BIIB122); and neuropsychiatric, immunology, acute neurology, and neuropathic pain conditions (BIIB125, BIIB104, Dapirolizumab pegol, BIIB059, BIIB093, BIIB131, BIIB074). Additional biosimilars, BYOOVIZ, BIIB800, and SB15, are also progressing through various development phases. Biogen has established extensive collaboration and licensing agreements with key industry partners, including Acorda Therapeutics, Inc., Alkermes Pharma Ireland Limited, Denali Therapeutics Inc., Eisai Co., Ltd., Genentech, Inc., Neurimmune SubOne AG, Ionis Pharmaceuticals, Inc., Samsung Bioepis Co., Ltd., Sangamo Therapeutics, Inc., and Sage Therapeutics, Inc. Founded in 1978, Biogen Inc. operates from its headquarters in Cambridge, Massachusetts.
www.biogen.comNo one on the platform currently holds IDP.DE.
No tracked institution reports a position in IDP.DE as of their last filing.
No one on the platform has traded IDP.DE yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 9.0% | 11.1% | 17.6% | — | — | — |
| Rev. Growth % | -1.5% | -6.6% | ||||
| Profit Margin % | 13.6% | 17.3% | 24.3% | |||
| Free Cash Flow Margin % | 21.5% | 20.4% | 26.7% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $10.3B | +4.7% | $12.61 | $11.80–$13.17 | — | 1 |
| 2027 | $10.5B | +2.0% | $16.41 | $15.36–$17.14 | — | 1 |
| 2028 | $10.8B | +2.9% | $18.62 | $17.43–$19.45 | — | 1 |
| 2029 | $11.0B | +2.3% | $20.54 | $19.23–$21.46 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-04-29 | $2.64 | $3.09 | +17.0% |
| 2026-02-06 | $1.38 | $1.69 | +22.5% |
| 2025-10-30 | $3.31 | $4.10 | +23.9% |
| 2025-07-31 | $3.31 | $4.64 | +40.2% |
| 2025-05-01 | $2.68 | $2.79 | +4.1% |
| 2025-02-12 | $3.22 | $3.32 | +3.1% |
| 2024-10-30 | $3.39 | $3.66 | +8.0% |
| 2024-08-01 | $3.80 |
| $4.93 |
| +29.7% |
| $12.7B |
| — |
| FME.DEFresenius Medical Care AG & Co. KGaA | $39.78 | +0.56% | $10.6B | — |
| GE9.FGenmab A/S | $292.00 | +3.88% | $18.0B | — |
Source: Financial Modeling Prep · peers by sector/industry